Advertisement

Geriatrische Aspekte bei Diabetes mellitus (Update 2019)

  • Joakim HuberEmail author
  • Michael Smeikal
  • Christoph H. Saely
  • Harald Stingl
  • Monika Lechleitner
  • Peter Fasching
leitlinien für die praxis
  • 15 Downloads

Zusammenfassung

Es besteht eine hohe Prävalenz an Diabetes mellitus Typ 2 bei über 70-Jährigen in industrialisierten Ländern. Dieser Artikel enthält Empfehlungen für Diagnose, Prävention und Therapieziele in der Behandlung des älteren diabetischen Patienten anhand der aktuellen Evidenzlage.

Schlüsselwörter

Geriatrische Aspekte Diabetes Therapie Empfehlungen Glukose Schulung Alter Diagnose Individualisierung Funktionelle Abhängigkeit 

Geriatric aspects for the management of diabetes mellitus (Update 2019)

Summary

There is a high prevalence of diabetes mellitus in the elderly population of industrial countries. The present article provides recommendations for the screening, prevention and treatment of elderly diabetic patients according to current scientific evidence.

Keywords

Geriatric Elderly Diabetes Therapy Recommendations Glucose Educational training Diagnosis 

Notes

Interessenkonflikt

J. Huber hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Fortbildungsunterstützung und/oder Honorare für Vorträge und Beratung erhalten: Eli Lilly, Novartis, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, sanofi-aventis, Merck Sharp & Dohme, Roche, Daiichi-Sankyo, Takeda. Zusätzlich gibt J. Huber an, dass für ihn persönlich kein Interessenkonflikt vorliegt. M. Smeikal hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Fortbildungsunterstützung und/oder Honorare für Vorträge erhalten: Abbott, Eli Lilly, Novartis, Pfizer, Servier, Amgen, AstraZeneca, sanofi-aventis. Zusätzlich gibt M. Smeikal an, dass für ihn persönlich kein Interessenkonflikt vorliegt. C. H. Saely hat von folgenden Firmen Honorare für Vorträge, Beratungstätigkeit und Forschungsunterstützung erhalten: Amgen, AstraZeneca, Boehringer-Ingelheim, Eli-Lilly, Genericon, Genzyme, Merck, MSD, Novo Nordisk, Pfizer, Sanofi. H. Stingl hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Eli Lilly, Novartis, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, sanofi-aventis, Roche, Takeda. Zusätzlich gibt H. Stingl an, dass für ihn persönlich kein Interessenkonflikt vorliegt. Er legt offen, dass er in diesem Zeitraum von den genannten Firmen Honorare für Vorträge und Beratung erhalten hat bzw. Fortbildungsunterstützung im Rahmen der (dienst)rechtlichen Rahmenbedingungen bezogen hat (Einladung zu Kongressen). M. Lechleitner hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Honorare erhalten: Boehringer Ingelheim, Merck Sharp & Dome, Novartis, Novo Nordisk, Pfizer, sanofi-aventis. P. Fasching hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott, AstraZeneca, Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Germania Pharmazeutika, GlaxoSmithKline Pharma, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, sanofi-aventis, Servier, Takeda. Zusätzlich gibt P. Fasching an, dass für ihn persönlich kein Interessenkonflikt vorliegt. Er legt offen, dass er in diesem Zeitraum von den genannten Firmen Honorare für Vorträge und Consulting erhalten bzw. Fortbildungsunterstützung im Rahmen der (dienst)rechtlichen Rahmenbedingungen bezogen hat (Einladung zu Kongressen) bzw. klinische Studien als PI mit einzelnen Firmen durchgeführt hat bzw. durchführt.

Literatur

  1. 1.
    Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;  https://doi.org/10.1007/s00125-002-1025-0.CrossRefPubMedGoogle Scholar
  2. 2.
    The DECODE study group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;  https://doi.org/10.2337/diacare.26.1.61.CrossRefGoogle Scholar
  3. 3.
    2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S13–S27Google Scholar
  4. 4.
    Roden M. Diabetes mellitus – Definition, Klassifikation und Diagnose. Wien Klin Wochenschr. 2016;128(Suppl 2):S37–S40.CrossRefPubMedGoogle Scholar
  5. 5.
    Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000.  https://doi.org/10.2337/diacare.23.2.176.CrossRefPubMedGoogle Scholar
  6. 6.
    Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007.  https://doi.org/10.1001/archinte.167.9.921.CrossRefPubMedGoogle Scholar
  7. 7.
    Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD. Hospitalization and mortality of diabetes in older adults: a 3‑year prospective study. Diabetes Care. 1998.  https://doi.org/10.2337/diacare.21.2.231.CrossRefPubMedGoogle Scholar
  8. 8.
    Tancredi M, Rosengren A, Svensson A‑M, Kosiborod M, Pivodic A, Gudbjörnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015.  https://doi.org/10.1056/NEJMoa1504347.CrossRefPubMedGoogle Scholar
  9. 9.
    Diabetes Prevention Program Research Group, Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group. Diabetes prevention program research group reduction in the incidence of type 2 diabetes with lifestyle intervention metformin. N Engl J Med. 2002.  https://doi.org/10.1016/j.biotechadv.2011.08.021.Secreted.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Jefferis BJ, Lennon L, Whincup PH, Wannamethee SG. Longitudinal associations between changes in physical activity and onset of type 2 diabetes in older British men: the influence of adiposity. Diabetes Care. 2012.  https://doi.org/10.2337/dc11-2280.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011.  https://doi.org/10.1056/NEJMoa1008234.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Meneilly GS, Knip A, Miller DB, Sherifali D, Tessier D, Zahedi A. Diabetes in older people. Can J Diabetes. 2018.  https://doi.org/10.1016/j.jcjd.2017.10.021.CrossRefPubMedGoogle Scholar
  13. 13.
    Dorner B. Position of the American Dietetic Association: individualized nutrition approaches for older adults in health care communities [corrected] [published erratum appears in J Am Diet Assoc 2010 Dec;110(12):1941. J Am Diet Assoc. 2010.  https://doi.org/10.1016/j.jada.2010.08.022.CrossRefPubMedGoogle Scholar
  14. 14.
    Volkert D, Bauer J, Frühwald T, Gehrke I, Lechleitner M, Lenzen-Großimlinghaus R, et al. Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der GESKES, der AKE und der DGG. Aktuel Ernahrungsmed. 2013.  https://doi.org/10.1055/s-0033-1343169.CrossRefGoogle Scholar
  15. 15.
    Evans WJ. Protein nutrition, exercise and aging. J Am Coll Nutr. 2004.  https://doi.org/10.1080/07315724.2004.10719430.CrossRefPubMedGoogle Scholar
  16. 16.
    Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al. Frailty in older adults: a nationally representative profile in the United States. J Gerontol A Biol Sci Med Sci. 2015.  https://doi.org/10.1093/gerona/glv133.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kalyani RR, Tian J, Xue QL, Walston J, Cappola AR, Fried LP, et al. Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women. J Am Geriatr Soc. 2012.  https://doi.org/10.1111/j.1532-5415.2012.04099.x.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002.  https://doi.org/10.2337/diacare.25.3.471.CrossRefPubMedGoogle Scholar
  19. 19.
    Gregg EW, Beckles GLA, Williamson DF, Leveille SG, Langlois JA, Engelgau MM, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000.  https://doi.org/10.2337/diacare.23.9.1272.CrossRefPubMedGoogle Scholar
  20. 20.
    Krop JS, Powe NR, Weller WE, Shaffer TJ, Saudek CD, Anderson GF. Patterns of expenditures and use of services among older adults with diabetes: implications for the transition to capitated managed care. Diabetes Care. 1998.  https://doi.org/10.2337/diacare.21.5.747.CrossRefPubMedGoogle Scholar
  21. 21.
    Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001.  https://doi.org/10.1093/gerona/56.3.M146.CrossRefPubMedGoogle Scholar
  22. 22.
    Sinclair A, Morley J. Frailty and diabetes. Lancet. 2013.  https://doi.org/10.1016/S0140-6736(13)61676-1.CrossRefPubMedGoogle Scholar
  23. 23.
    Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010.  https://doi.org/10.1093/ageing/afq034.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenburg J, Nilwik R, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc. 2013.  https://doi.org/10.1016/j.jamda.2013.02.006.CrossRefPubMedGoogle Scholar
  25. 25.
    Volpato S, Bianchi L, Lauretani F, Lauretani F, Bandinelli S, Guralnik JM, et al. Role of muscle mass and muscle quality in the association between diabetes and gait speed. Diabetes Care. 2012.  https://doi.org/10.1016/j.jamda.2013.02.006.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014.  https://doi.org/10.1016/j.jamda.2014.04.021.CrossRefPubMedGoogle Scholar
  27. 27.
    Morley JE, Vellas B, Abellan van Kan G, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013.  https://doi.org/10.1016/j.jamda.2013.03.022.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bahrmann A, Bahrmann P, Baumann J, Bauer J, Brückel E, Dreyer M, et al. S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter: 2. Auflage 2018 – AWMF-Register-Nr. 057-017. Diabetol Stoffwechsel. 2018.  https://doi.org/10.1055/a-0666-0820.CrossRefGoogle Scholar
  29. 29.
    Pariser G, Hager K, Gillette P, Golemboski K, Jackson K. Active steps for diabetes: a community-campus partnership addressing frailty and diabetes. Diabetes Educ. 2014.  https://doi.org/10.1177/0145721713514281.CrossRefPubMedGoogle Scholar
  30. 30.
    Gordon PL, Vannier E, Hamada K, Layne J, Hurley BF, Roubenoff R, et al. Resistance training alters cytokine gene expression in skeletal muscle of adults with type 2 diabetes. Int J Immunopathol Pharmacol. 2006.  https://doi.org/10.1177/039463200601900404.CrossRefPubMedGoogle Scholar
  31. 31.
    Reusch JEB, Bridenstine M, Regensteiner JG. Type 2 diabetes mellitus and exercise impairment. Rev Endocr Metab Disord. 2013.  https://doi.org/10.1007/s11154-012-9234-4.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the prot-age study group. J Am Med Dir Assoc. 2013.  https://doi.org/10.1016/j.jamda.2013.05.021.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Rawlings AM, Sharrett AR, Schneider ALC, Coresh J, Albert M, Couper D, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 2014.  https://doi.org/10.7326/M14-0737.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Li W, Huang E. An update on type 2 diabetes mellitus as a risk factor for dementia. J Alzheimers Dis. 2016.  https://doi.org/10.3233/JAD-160114.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, et al. Diabetes, glucose control, and 9‑year cognitive decline among older adults without dementia. Arch Neurol. 2012.  https://doi.org/10.1001/archneurol.2012.1117.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc. 2003.  https://doi.org/10.1001/jama.289.23.3095.CrossRefGoogle Scholar
  37. 37.
    Katon W, Pedersen HS, Ribe AR, Fenger-Grøn M, Davydow D, Waldorff FB, Vestergaard M. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry. 2015;72(6):612–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    van Dooren FEP, Nefs G, Schram MT, Verhey FRJ, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS ONE. 2013.  https://doi.org/10.1371/journal.pone.0057058.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care. 2003.  https://doi.org/10.2337/diacare.26.10.2822.CrossRefPubMedGoogle Scholar
  40. 40.
    Kimbro LB, Mangione CM, Steers WN, Duru OK, McEwen L, Karter A, et al. Depression and all-cause mortality in persons with diabetes mellitus: Are older adults at higher risk? Results from the translating research into action for diabetes study. J Am Geriatr Soc. 2014.  https://doi.org/10.1111/jgs.12833.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    American Diabetes Association. 11. Older adults: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S119–S25.CrossRefGoogle Scholar
  42. 42.
    Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011.  https://doi.org/10.2337/dc10-2377.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. (ACCORD study results). N Engl J Med. 2008.  https://doi.org/10.1056/NEJMoa0802743.CrossRefPubMedGoogle Scholar
  44. 44.
    Tan HH, McAlpine RR, James P, Thompson P, McMurdo MET, Morris AD, et al. Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care. 2004.  https://doi.org/10.2337/diacare.27.12.2797.CrossRefPubMedGoogle Scholar
  45. 45.
    Landgraf R, Kellerer M, Fach E, Gallwitz B, Hamann A, Joost HG, et al. Praxisempfehlungen DDG/DGIM: Therapie des Typ-2-Diabetes. Diabetol Stoffwechsel. 2013.  https://doi.org/10.1055/s-0033-1335297.CrossRefGoogle Scholar
  46. 46.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014.  https://doi.org/10.1001/jama.2013.284427.CrossRefPubMedGoogle Scholar
  47. 47.
    Kirkman SM, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012.  https://doi.org/10.1111/jgs.12035.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    American Diabetes Association. Diabetes care: standards of medical care in diabetes—2018. Diabetes Care. 2018.  https://doi.org/10.2337/dc18-S002.CrossRefGoogle Scholar
  49. 49.
    Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. (HyVET) treatment of hypertension in patients 80 years of age and older. N Engl J Med. 2008.  https://doi.org/10.1056/NEJMoa0801369.CrossRefPubMedGoogle Scholar
  50. 50.
    Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for themanagement of arterial hypertension. Eur Heart J. 2018.  https://doi.org/10.1093/eurheartj/ehy339.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016.  https://doi.org/10.1093/eurheartj/ehw272.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006.  https://doi.org/10.1212/01.wnl.0000224760.22802.e8.CrossRefPubMedGoogle Scholar
  53. 53.
    Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009.  https://doi.org/10.1212/01.wnl.0000224760.22802.e8.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009.  https://doi.org/10.1001/jama.2009.460.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman-Yaffee T, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012.  https://doi.org/10.2337/dc11-1855.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.[see comment][erratum appears in JAMA. 2003 Jul 9;290(2):197. JAMA. 2003.  https://doi.org/10.1001/jama.289.19.2560.CrossRefPubMedGoogle Scholar
  57. 57.
    SPRINT, Wright JT, Williamson JD, Whelton PSK, Snyder JK, Sink KM, Rocco MV, et al. BP targets in high-risk patients. N Engl J Med. 2015.  https://doi.org/10.1056/NEJMoa1511939.CrossRefGoogle Scholar
  58. 58.
    Schäfer HH, De Villiers JN, Sudano I, Dischinger S, Theus GR, Zilla P, et al. Recommendations for the treatment of hypertension in the elderly and very elderly—a scotoma within international guidelines. Swiss Med Wkly. 2012.  https://doi.org/10.4414/smw.2012.13574.CrossRefPubMedGoogle Scholar
  59. 59.
    Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002.  https://doi.org/10.1016/S0140-6736(02)09327-3.CrossRefPubMedGoogle Scholar
  60. 60.
    Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002.  https://doi.org/10.1016/S0140-6736(02)11600-X.CrossRefPubMedGoogle Scholar
  61. 61.
    Forman D, Wenger NK. What do the recent American Heart Association/American College of Cardiology Foundation clinical practice guidelines tell us about the evolving management of coronary heart disease in older adults? J Geriatr Cardiol. 2013.  https://doi.org/10.3969/j.issn.1671-5411.2013.02.012.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002.  https://doi.org/10.1046/j.1464-5491.2002.00689.x.CrossRefPubMedGoogle Scholar
  63. 63.
    Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011.  https://doi.org/10.2337/dc10-2361.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Diabetologia. 2015.  https://doi.org/10.1007/s00125-014-3460-0.CrossRefPubMedGoogle Scholar
  65. 65.
    Kos E, Liszek M, Emanuele M, Durazo-Arvizu R, Camacho P. Effect of Metformin therapy on vitamin D and vitamin B12 levels in patients with type 2 diabetes mellitus. Endocr Pract. 2012.  https://doi.org/10.4158/EP11009.OR.CrossRefPubMedGoogle Scholar
  66. 66.
    De Jager J, Kooy A, Lehert P, Wulffelé MG, Van Der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B‑12 deficiency: randomised placebo controlled trial. BMJ. 2010.  https://doi.org/10.1136/bmj.c2181.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Ting RZW, Szeto CC, Chan MHM, Ma KK, Chow KM. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med. 2006.  https://doi.org/10.1001/archinte.166.18.1975.CrossRefPubMedGoogle Scholar
  68. 68.
    Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016.  https://doi.org/10.1210/jc.2015-3754.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3 year trial. J Diabetes Complicat. 2018.  https://doi.org/10.1016/j.jdiacomp.2017.11.001.CrossRefPubMedGoogle Scholar
  70. 70.
    Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012.  https://doi.org/10.1038/nrendo.2011.243.CrossRefPubMedGoogle Scholar
  71. 71.
    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG. N Engl J Med. 2015.  https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMedGoogle Scholar
  72. 72.
    Monteiro P, Schaper N, Clark D, Hantel S, Woerle HJ, Inzucchi SE, et al. Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG outcome. Diabetes Conf 76th Sci Sess Am diabetes Assoc ADA 2016. 2016.Google Scholar
  73. 73.
    Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014.  https://doi.org/10.1111/dom.12244.CrossRefPubMedGoogle Scholar
  74. 74.
    Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013.  https://doi.org/10.1016/j.jdiacomp.2013.04.012.CrossRefPubMedGoogle Scholar
  75. 75.
    Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013.  https://doi.org/10.1016/j.jdiacomp.2013.05.004.CrossRefPubMedGoogle Scholar
  76. 76.
    Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014.  https://doi.org/10.1185/03007995.2014.890925.CrossRefPubMedGoogle Scholar
  77. 77.
    Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013.  https://doi.org/10.1016/S0140-6736(13)60683-2.CrossRefPubMedGoogle Scholar
  78. 78.
    Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013.  https://doi.org/10.2337/dc12-2491.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013.  https://doi.org/10.7326/0003-4819-159-4-201308200-00007.CrossRefPubMedGoogle Scholar
  80. 80.
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006.  https://doi.org/10.1016/S0140-6736(06)69705-5.CrossRefPubMedGoogle Scholar
  81. 81.
    Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005.  https://doi.org/10.1016/S0140-6736(05)67528-9.CrossRefPubMedGoogle Scholar
  82. 82.
    Stafford S, Elahi D, Meneilly GS. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2011.  https://doi.org/10.1111/j.1532-5415.2011.03438.x.CrossRefPubMedGoogle Scholar
  83. 83.
    Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011.  https://doi.org/10.1185/03007995.2011.568059.CrossRefPubMedGoogle Scholar
  84. 84.
    Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010.  https://doi.org/10.1016/j.amjopharm.2010.10.003.CrossRefPubMedGoogle Scholar
  85. 85.
    Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009.  https://doi.org/10.1111/j.1532-5415.2009.02484.x.CrossRefPubMedGoogle Scholar
  86. 86.
    Defronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008.  https://doi.org/10.2337/dc08-1035.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012.  https://doi.org/10.1111/j.1463-1326.2011.01523.x.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011.  https://doi.org/10.1111/j.1463-1326.2011.01458.x.CrossRefPubMedGoogle Scholar
  89. 89.
    Van de Laar Floris A, Lucassen Peter LBJ, Akkermans Reinier P, Van de Lisdonk Eloy H, Rutten Guy EHM, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005.  https://doi.org/10.1002/14651858.CD003639.pub2.CrossRefGoogle Scholar
  90. 90.
    Braun AK, Kubiak T, Kuntsche J, Meier-Höfig M, Müller UA, Feucht I, et al. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus—a prospective randomised controlled multi-centre trial. Age Ageing. 2009.  https://doi.org/10.1093/ageing/afp056.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Sinclair A, Morley JE, Rodriguez-Mañas L, Paolisso G, Bayer T, Zeyfang A, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012.  https://doi.org/10.1016/j.jamda.2012.04.012.CrossRefPubMedGoogle Scholar
  92. 92.
    Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018.  https://doi.org/10.2337/dci18-0033.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Joakim Huber
    • 1
    Email author
  • Michael Smeikal
    • 2
  • Christoph H. Saely
    • 3
  • Harald Stingl
    • 4
  • Monika Lechleitner
    • 5
  • Peter Fasching
    • 6
  1. 1.Interne Abteilung mit Akutgeriatrie und PalliativstationFranziskus SpitalWienÖsterreich
  2. 2.Abteilung für Innere Medizin mit allgemeiner Geriatrie und PalliativmedizinHaus der BarmherzigkeitWienÖsterreich
  3. 3.Abteilung für Innere Medizin und Kardiologie/VIVIT-InstitutAkademisches Lehrkrankenhaus FeldkirchFeldkirchÖsterreich
  4. 4.Interne AbteilungLandesklinikum MelkMelkÖsterreich
  5. 5.Interne AbteilungLandeskrankenhaus Hochzirl-NattersHochzirlÖsterreich
  6. 6.Medizinische Abteilung für Endokrinologie, Rheumatologie und AkutgeriatrieWilhelminenspital der Stadt WienWienÖsterreich

Personalised recommendations